Radiopharm - anyone know how this compares to TLX?

RADIOPHARM THERANOSTICS CLOSES A$152M ASX IPO HEAVILY OVERSUBSCRIBED

• Radiopharm Theranostics is focused on development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs
• Highly prospective portfolio of four distinct & clearly differentiated platform technologies
• Pipeline candidate selection based on their potential to be First to Market or Best in Class in the respective therapeutic applications
• Deep clinical pipeline of five Phase 2 trials and two Phase 1 trials ongoing, with a total of 133 patients dosed to date
• Key executives secured including former AAA/Novartis CCO Riccardo Canevari as CEO & MD, Prof David Mozley as CMO and Dr Thom Tulip as CTO
• Radiopharm raised A$50m as part of the IPO, listing with a market capitalisation of A$152m under the code RAD
• The IPO closed heavily oversubscribed, with strong support from a range of institutional, sophisticated and retail investors both locally and overseas
• Expected to list on the ASX Thursday 25 November 2021
• Founded by Australian biotech entrepreneur Paul Hopper, who will have a 35.53% shareholding upon listing
• Bell Potter and Baker Young are Joint Lead Managers to the IPO